IPO
Novo Seeds, the early stage investment and company creation team of Novo Holdings, publishes its review of 2019 - a year of significant progress and growth.
NBE-Therapeutics AG announces the closing of a USD 22M Series C financing round, led by its existing shareholders Boehringer Ingelheim Venture Fund and the PPF Group and with participation from all private shareholders.
Grey Wolf targets ERAP antigen presentation pathways with the aim of ‘illuminating’ non-responsive tumors for attack and destruction by the immune system
Funding to Support Ongoing Advancement of siFi2, Lead Candidate from Company’s First-of-its-Kind Platform for Precisely Controlling Core Cell Migration Mechanisms
The Novo Holdings REPAIR Impact Fund announced a EUR 7 million investment in Mutabilis, a company developing novel antibacterials against Gram-negative infections based near Paris, France.
The clinically integrated ancillary care platform will accelerate expansion into local gastroenterology (GI) practices to provide specialized care for the rising NonAlcoholic SteatoHepatitis (NASH) epidemic
Parnell announces 2019 year-to-date revenue growth of 9% over the first 9 months of 2018, start of work on its new 2019 CMO contract, and updates to 2019 financial results.
Here’s a look at some of the biggest U.S. Nasdaq-based initial public offerings in 2019 and some of the more intriguing ones.
Genomill Health closes a financing round led by a deep tech VC Voima Ventures to expand its novel and disruptive technology, focusing on efficient use of NGS in liquid biopsies for cancer diagnostics.
This year’s edition saw a rise in overall attendees, with harmonization and innovation driving increased industry dynamism
PRESS RELEASES